Key Developments: Active Biotech AB (ACTI.ST)

ACTI.ST on Stockholm Stock Exchange

8.85SEK
3 Jul 2015
Change (% chg)

-0.15kr (-1.67%)
Prev Close
9.00kr
Open
9.05kr
Day's High
9.05kr
Day's Low
8.85kr
Volume
32,955
Avg. Vol
273,387
52-wk High
33.60kr
52-wk Low
8.45kr

Search Stocks

Latest Key Developments (Source: Significant Developments)

Active Biotech says patient enrollment in laquinimod trial completed
Thursday, 25 Jun 2015 08:01am EDT 

Active Biotech AB:Active Biotech: Teva and Active Biotech announce completion of patient enrollment in laquinimod phase III Concerto trial.Says Concerto study results are expected to be available toward mid-2017.  Full Article

Active Biotech AB plans redundancies of 47 employees, downsizes operations
Monday, 1 Jun 2015 04:01am EDT 

Active Biotech AB:Says focuses the operations on the laquinimod project and adjusts the organization.Made a notification of planned redundancies of 47 of employees, which means a down-sizing of operations.Operating costs are expected to decrease to about 50 million Swedish crowns per year, from 2016.Says planned organizational adjustment leads to substantially reduced operating costs.  Full Article

Active Biotech and Ipsen to stop development of Tasquinimod in prostate cancer
Thursday, 16 Apr 2015 01:00am EDT 

Active Biotech AB:Active Biotech and Ipsen SA announce their decision to discontinue the development of Tasquinimod in prostate cancer.Efficacy results together with preliminary safety data do not support positive benefit risk balance.Full results will be presented at an upcoming scientific conference.  Full Article

Active Biotech says SEK 225 million rights issue oversubscribed
Monday, 29 Dec 2014 09:30am EST 

Active Biotech AB:Active Biotech's rights issue of about 225 million Swedish crowns oversubscribed.  Full Article

Active Biotech and Teva expand laquinimod clinical development program
Tuesday, 4 Nov 2014 08:00am EST 

Active Biotech AB:Teva and Active Biotech announce expansion of Laquinimod clinical development program with new trial in primary progressive multiple sclerosis and first patient screened in Huntington's Disease trial.  Full Article

Active Biotech AB's partner Teva initiates laquinimod clinical trial in Huntington's disease
Thursday, 14 Aug 2014 02:36am EDT 

Active Biotech AB:Says its partner Teva Pharmaceutical Industries Ltd. will initiate phase II clinical trial to evaluate efficacy and safety of oral laquinimod for treatment of Huntington's disease.  Full Article

Teva Pharmaceutical Industries Ltd and Active Biotech to continue with development of Nerventra for Multiple Sclerosis following confirmation of CHMP Opinion
Friday, 23 May 2014 02:30am EDT 

Teva Pharmaceutical Industries Ltd and Active Biotech:Committee for Medicinal Products for Human Use (CHMP) confirmed Jan. 23, opinion to recommend against approval for treatment of relapsing-remitting multiple sclerosis (RRMS) in European Union (EU) at this time.Both companies remain committed to NERVENTRA (laquinimod) clinical development program for multiple sclerosis (MS) and are focused on evaluating the CHMP feedback to determine potential next steps.To further confirm benefits of NERVENTRA on disability progression, Teva is conducting the CONCERTO trial, MS trial with disability progression as the primary endpoint.Says ongoing CONCERTO trial is third Phase III study in RRMS and explores daily doses of NERVENTRA 0.6 mg and 1.2 mg.In addition, Teva is investigating potential of NERVENTRA in progressive forms of MS.Says first trial for this indication is planned to be initiated soon.  Full Article

Active Biotech AB proposes no dividend for FY 2013
Monday, 14 Apr 2014 02:30am EDT 

Active Biotech AB:Says its board proposes that no dividend be paid for FY 2013.No dividend was paid for FY 2012.  Full Article

Active Biotech says Teva changes clinical development program for laquinimod
Wednesday, 19 Feb 2014 08:00am EST 

Active Biotech AB:Says the company's partner, Teva Pharmaceuticals, has decided not to proceed to the randomization stage of the planned Libretto trial for the treatment of Relapsing Remitting Multiple Sclerosis (RRMS).Says the reason is that the current design is no longer aligned with the regulatory strategy.Says the decision has no impact on other ongoing studies, such as CONCERTO, which are proceeding as planned, or on Teva Pharmaceuticals' plans to initiate clinical studies in Primary Progressive Multiple Sclerosis (PPMS).  Full Article

Teva and Active Biotech to continue development of NERVENTRA despite negative opinion from EMA's CHMP
Friday, 24 Jan 2014 07:03am EST 

Active Biotech AB:Says Teva Pharmaceutical Industries Ltd. and Active Biotech remain committed to the NERVENTRA (laquinimod) clinical development program for multiple sclerosis (MS).Says this statement follows the announcement of a negative opinion for the treatment of relapsing-remitting multiple sclerosis (RRMS) by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA).Says CHMP has concluded that the risk-benefit profile of NERVENTRA is not favorable at this time.Says Teva and Active Biotech intend to request a re-examination of the CHMP opinion.  Full Article

BRIEF-Active Biotech says patient enrollment in laquinimod trial completed

* Active Biotech: Teva and Active Biotech announce completion of patient enrollment in laquinimod phase III Concerto trial

Search Stocks